All In Biotech

Drug Trial Radar · NCT03072238

Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Jun 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,101 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,101

Actual

Start

Jun 30, 2017

Primary completion

Mar 16, 2020

Study completion Apr 24, 2024

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Mar 7, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ipatasertib plus abiraterone and prednisone/prednisolone compared with placebo plus abiraterone and prednisone/prednisolone in participants with metastatic castrate-resistant prostate cancer (mCRPC).

Conditions

  • Metastatic Prostate Cancer

Interventions

  • IpatasertibDrug

    Oral tablets, 400 mg, given once daily (QD) beginning on Day 1 of Cycle 1 until disease progression or intolerable toxicity.

  • AbirateroneDrug

    Oral tablets of abiraterone, 1000 mg QD, taken on an empty stomach and swallowed whole with water.

  • PlaceboDrug

    Oral tablets (matched to ipatasertib appearance), given QD beginning on Day 1 of Cycle 1 until disease progression or intolerable toxicity.

  • Prednisone/PrednisoloneDrug

    Oral tablets of 5 mg, taken twice daily (BID) until disease progression or intolerable toxicity.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Investigator-assessed Radiographic Progression-free Survival (rPFS), Per Prostate Cancer Working Group 3 (PCWG3) Criteria in Phosphatase and Tensin Homolog (PTEN) Loss PopulationTime frame: Up to approximately 32 months
  2. Investigator-assessed rPFS, Per PCWG3 Criteria in ITT PopulationTime frame: Up to approximately 32 months

Locations

176 sites in 26 countries. Site status is shown where the registry gives one.

  • Ironwood Cancer & Research Centers

    Chandler, Arizona

  • Mayo Clinic Arizona

    Scottsdale, Arizona

  • City of Hope

    Duarte, California

  • USC Norris Cancer Center

    Los Angeles, California

  • UC Irvine Medical Center

    Orange, California

  • Stanford University

    Palo Alto, California

  • Pacific Hematology Oncology Associates

    San Francisco, California

  • University of Colorado Hospital - Anschutz Cancer Pavilion

    Aurora, Colorado

  • Yale Cancer Center

    New Haven, Connecticut

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • Lynn Cancer Institute/Boca Raton Regional Hospital

    Boca Raton, Florida

  • Miami Cancer Institute of Baptist Health, Inc.

    Miami, Florida

  • Northside Hospital

    Atlanta, Georgia

  • Illinois Cancer Care

    Peoria, Illinois

  • Associates in Oncology/Hematology P.C.

    Rockville, Maryland

  • Tufts Medical Center

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan

  • Karmanos Cancer Institute..

    Detroit, Michigan

  • HCA Midwest Division

    Kansas City, Missouri

  • Urology Cancer Center & GU Research Network

    Omaha, Nebraska

  • Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley

    Las Vegas, Nevada

  • Hackensack Univ Medical Center

    Hackensack, New Jersey

  • Cleveland Clinic

    Cleveland, Ohio

  • Northwest Cancer Specialists, P.C.

    Tualatin, Oregon

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Allegheny Cancer Center

    Pittsburgh, Pennsylvania

  • Rhode Island Hospital

    Providence, Rhode Island

  • Charleston Oncology, P .A

    Charleston, South Carolina

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina

  • Texas Oncology - Gulf Coast

    The Woodlands, Texas

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • Macquarie University Hospital

    Macquarie University, New South Wales, Australia

  • Adelaide Cancer Centre

    Kurralta Park, South Australia, Australia

  • Monash Medical Centre

    EAST Bentleigh, Victoria, Australia

  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, Australia

  • Eastern Health

    Melbourne, Victoria, Australia

  • Lkh-Univ. Klinikum Graz

    Graz, Austria

  • Ordensklinikum Linz Elisabethinen

    Linz, Austria

  • Landeskrankenhaus Salzburg

    Salzburg, Austria

Showing 40 of 176 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.